Esperion Therapeutics, Inc. (ESPR)
3.13
+0.01
(+0.32%)
USD |
NASDAQ |
May 18, 12:48
Esperion Therapeutics Research and Development Expense (Quarterly) : 8.988M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 11.98B |
| Nektar Therapeutics | 35.68M |
| Harrow, Inc. | 5.895M |
| Corcept Therapeutics, Inc. | 66.26M |
| Eli Lilly & Co. | 3.51B |